Biosimilar uptake driven by a country’s healthcare system, says IMS Health
Countries with a tender-based healthcare system are adopting biosimilars at a far greater rate than those without, according to IMS Health.
Countries with a tender-based healthcare system are adopting biosimilars at a far greater rate than those without, according to IMS Health.
BioLife Solutions has partnered with transportation firm MNX and says it expects increased demand for its biologistics services as more cell therapies enter the clinic.